Exosomal MiR-21-5p Derived from Cisplatin-resistant SKOV3 Ovarian Cancer Cells Promotes Glycolysis and Inhibits Chemosensitivity of Its Progenitor SKOV3 Cells by Targeting PDHA1
Overview
Affiliations
Ovarian cancer (OC) is a common reason for gynecologic cancer death. Standard treatments of OC consist of surgery and chemotherapy. However, chemoresistance should be considered. Exosomal miR-21-5p has been shown to regulate the chemosensitivity of cancer cells through regulating pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1). However, the role of miR-21-5p/PDHA1 in OC is unclear. The levels of miR-21-5p and PDHA1 in clinical samples and cells were investigated. Exosomes derived from SKOV3/cisplatin (SKOV3/DDP) cells (DDP-Exos) were isolated and used to treat SKOV3 cells to test DDP-Exos effects on SKOV3 cells. Extracellular acidification rate and oxygen consumption rate were tested with a Seahorse analyzer. Cell apoptosis was analyzed by a flow cytometer. PDHA1 was overexpressed and miR-21-5p was silenced in SKOV3 cells to study the underlying mechanism of miR-21-5p in OC. Quantitative real-time PCR and immunoblots were applied to measure gene expression at mRNA and protein levels. The levels of PDHA1 in DDP-resistant SKOV3 or tumor tissues were significantly decreased while the levels of miR-21-5p were remarkably upregulated. miR-21-5p in DDP-Exos was sharply increased compared to that of Exos. Data also indicated that DDP-Exos treatment suppressed the sensitivity of SKOV3 cells to DDP and promoted cell viability and glycolysis of SKOV3 cells through inhibiting PDHA1 by exosomal miR-21-5p. miR-21-5p derived from DDP-resistant SKOV3 OC cells promotes glycolysis and inhibits chemosensitivity of its progenitor SKOV3 cells by targeting PDHA1. Our data highlights the important role of miR-21-5p/PDHA1 axis in OC and sheds light on new therapeutic development.
Peng L, Lai Y, Cao B Front Oncol. 2025; 15:1526944.
PMID: 40008006 PMC: 11850269. DOI: 10.3389/fonc.2025.1526944.
Extracellular Vesicles as Mediators and Potential Targets in Combating Cancer Drug Resistance.
Zhang H, Wu B, Wang Y, Du H, Fang L Molecules. 2025; 30(3).
PMID: 39942602 PMC: 11819960. DOI: 10.3390/molecules30030498.
Tuscharoenporn T, Apaijai N, Charoenkwan K, Chattipakorn N, Chattipakorn S Cancer Gene Ther. 2025; 32(2):149-164.
PMID: 39843770 DOI: 10.1038/s41417-025-00871-2.
Shi J, Shen Y, Zhang J Cancer Drug Resist. 2024; 7:38.
PMID: 39403606 PMC: 11472704. DOI: 10.20517/cdr.2024.81.
Intercellular transfer of multidrug resistance mediated by extracellular vesicles.
Yang A, Sun H, Wang X Cancer Drug Resist. 2024; 7:36.
PMID: 39403600 PMC: 11472569. DOI: 10.20517/cdr.2024.84.